Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MT-103 Micromet/MedImmune.

Eleanor J Cheadle1

  • 1Paterson Institute for Cancer Research, Department of Medical Oncology, Wilmslow Road, Manchester M204BX, UK. Echeadle@picr.man.ac.uk

Current Opinion in Molecular Therapeutics
|March 2, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Tumour Immune Microenvironment as a Predictor of the Response to Neoadjuvant Therapy in Rectal Cancer.

Cancers·2026
Same author

Longitudinal plasma nano-proteomics reveals acute systemic responses to radiotherapy and predictive biomarkers of late toxicity.

Communications medicine·2026
Same author

Investigating the Immune Effects of Radiotherapy in Non-Small Cell Lung Cancer-Results of the PD-RAD Study.

Oncology research·2026
Same author

CCR2-driven monocyte recruitment is protective against radiotherapy-induced intestinal toxicity.

Mucosal immunology·2025
Same author

Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies.

Frontiers in cell and developmental biology·2023
Same author

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.

Oncoimmunology·2023
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

MT-103, a bispecific T-cell engager, targets CD19 and T-cells for B-cell lymphoma. This antibody therapy is also being explored for chronic lymphocytic leukemia and acute lymphoblastic leukemia.

Area of Science:

  • Oncology
  • Immunotherapy
  • Biotechnology

Background:

  • B-cell malignancies like lymphoma and leukemia are significant health concerns.
  • Targeted therapies are crucial for improving treatment outcomes.
  • Bispecific T-cell engagers offer a novel approach to cancer immunotherapy.

Purpose of the Study:

  • To introduce MT-103, a novel bispecific antibody for cancer treatment.
  • To highlight the therapeutic potential of MT-103 in B-cell malignancies.

Main Methods:

  • Development of MT-103, a single-chain bispecific recombinant antibody.
  • Utilizing Micromet's BiTE (bispecific T-cell engager) platform.
  • Designing the antibody to bind CD19 and the T-cell receptor (CD3).

Related Experiment Videos

Main Results:

  • MT-103 demonstrates dual binding to CD19 and CD3.
  • Potential for T-cell mediated lysis of CD19-expressing cancer cells.

Conclusions:

  • MT-103 shows promise as a targeted therapy for B-cell lymphoma.
  • Further investigation is warranted for its use in chronic lymphocytic leukemia and acute lymphoblastic leukemia.